

## DAFTAR PUSTAKA

- Ali, A., & Ahmed, S. (2018). A review on chitosan and its nanocomposites in drug delivery. *Int J Biol Macromol*, 109, 273-286. <https://doi.org/10.1016/j.ijbiomac.2017.12.078>
- An, N., & Zheng, B. (2020). MiR-203a-3p Inhibits Pancreatic Cancer Cell Proliferation, EMT, and Apoptosis by Regulating SLUG. *Technology in Cancer Research & Treatment*, 19, 1533033819898729. <https://doi.org/10.1177/1533033819898729>
- Anwar, S. L., Sari, D. N. I., Kartika, A. I., Fitria, M. S., Tanjung, D. S., Rakhmina, D., Wardana, T., Astuti, I., Haryana, S. M., & Aryandono, T. (2019). Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and Clinical Outcome in Breast Cancer. *Asian Pac J Cancer Prev*, 20(4), 1223-1228. <https://doi.org/10.31557/APJCP.2019.20.4.1223>
- Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019). Antibody-Drug Conjugate-Based Therapeutics: State of the Science. *J Natl Cancer Inst*, 111(6), 538-549. <https://doi.org/10.1093/jnci/djz035>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*, 68(6), 394-424. <https://doi.org/10.3322/caac.21492>
- Cai, K. T., Feng, C. X., Zhao, J. C., He, R. Q., Ma, J., & Zhong, J. C. (2018). Upregulated miR-203a-3p and its potential molecular mechanism in breast cancer: A study based on bioinformatics analyses and a comprehensive meta-analysis. *Mol Med Rep*, 18(6), 4994-5008. <https://doi.org/10.3892/mmr.2018.9543>
- Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., Rassenti, L., Kipps, T., Negrini, M., Bullrich, F., & Croce, C. M. (2002). Frequent deletions and down-regulation of micro- RNA genes <i>miR15</i> and <i>miR16</i> at 13q14 in chronic lymphocytic leukemia. *Proceedings of the National Academy of Sciences*, 99(24), 15524-15529. <https://doi.org/doi:10.1073/pnas.242606799>
- Chen, T., Xu, C., Chen, J., Ding, C., Xu, Z., Li, C., & Zhao, J. (2015). MicroRNA-203 inhibits cellular proliferation and invasion by targeting Bmi1 in non-small cell lung cancer. *Oncol Lett*, 9(6), 2639-2646. <https://doi.org/10.3892/ol.2015.3080>
- Chen, X., Gu, S., Chen, B. F., Shen, W. L., Yin, Z., Xu, G. W., Hu, J. J., Zhu, T., Li, G., Wan, C., Ouyang, H. W., Lee, T. L., & Chan, W. Y. (2015). Nanoparticle delivery of stable miR-199a-5p agomir improves the osteogenesis of human mesenchymal stem cells via the HIF1a pathway. *Biomaterials*, 53, 239-250. <https://doi.org/10.1016/j.biomaterials.2015.02.071>

- D'Ippolito, E., & Iorio, M. V. (2013). MicroRNAs and triple negative breast cancer. *Int J Mol Sci*, 14(11), 22202-22220. <https://doi.org/10.3390/ijms141122202>
- Dai, X., Li, Y., Bai, Z., & Tang, X.-Q. (2015). Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers. *Scientific Reports*, 5(1), 14499. <https://doi.org/10.1038/srep14499>
- Di Leva, G., Garofalo, M., & Croce, C. M. (2014). MicroRNAs in cancer. *Annu Rev Pathol*, 9, 287-314. <https://doi.org/10.1146/annurev-pathol-012513-104715>
- Ding, L., Zhang, Y., Han, L., Fu, L., Mei, X., Wang, J., Itkow, J., Elabid, A. E. I., Pang, L., & Yu, D. (2018). Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis. *Oncogene*, 37(10), 1293-1307. <https://doi.org/10.1038/s41388-017-0055-5>
- Dobie, C., & Skropeta, D. (2021). Insights into the role of sialylation in cancer progression and metastasis. *Br J Cancer*, 124(1), 76-90. <https://doi.org/10.1038/s41416-020-01126-7>
- Felli, N., Fontana, L., Pelosi, E., Botta, R., Bonci, D., Facchiano, F., Liuzzi, F., Lulli, V., Morsilli, O., Santoro, S., Valtieri, M., Calin, G. A., Liu, C. G., Sorrentino, A., Croce, C. M., & Peschle, C. (2005). MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. *Proc Natl Acad Sci U S A*, 102(50), 18081-18086. <https://doi.org/10.1073/pnas.0506216102>
- Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-negative breast cancer. *N Engl J Med*, 363(20), 1938-1948. <https://doi.org/10.1056/NEJMra1001389>
- Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006). Clonogenic assay of cells in vitro. *Nat Protoc*, 1(5), 2315-2319. <https://doi.org/10.1038/nprot.2006.339>
- Freitas, J. T., Jozic, I., & Bedogni, B. (2021). Wound Healing Assay for Melanoma Cell Migration. *Methods Mol Biol*, 2265, 65-71. [https://doi.org/10.1007/978-1-0716-1205-7\\_4](https://doi.org/10.1007/978-1-0716-1205-7_4)
- Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019). Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. *Cancer Discov*, 9(2), 176-198. <https://doi.org/10.1158/2159-8290.Cd-18-1177>
- Gatti, V., Bongiorno-Borbone, L., Fierro, C., Annicchiarico-Petruzzelli, M., Melino, G., & Peschiaroli, A. (2019). p63 at the Crossroads between Stemness and Metastasis in Breast Cancer. *International Journal of Molecular Sciences*, 20(11), 2683. <https://www.mdpi.com/1422-0067/20/11/2683>
- Ghirardello, M., Shyam, R., & Galan, M. C. (2022). Reengineering of cancer cell surface charges can modulate cell migration [10.1039/D2CC00402J]. *Chemical Communications*, 58(36), 5522-5525. <https://doi.org/10.1039/D2CC00402J>

- Gomes, B. C., Martins, M., Lopes, P., Morujão, I., Oliveira, M., Araújo, A., Rueff, J., & Rodrigues, A. S. (2016). Prognostic value of microRNA-203a expression in breast cancer. *Oncol Rep*, 36(3), 1748-1756. <https://doi.org/10.3892/or.2016.4913>
- Gong, C., Tian, J., Wang, Z., Gao, Y., Wu, X., Ding, X., Qiang, L., Li, G., Han, Z., Yuan, Y., & Gao, S. (2019). Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. *Journal of Nanobiotechnology*, 17(1), 93. <https://doi.org/10.1186/s12951-019-0526-7>
- Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. *Nature Reviews Molecular Cell Biology*, 15(8), 509-524. <https://doi.org/10.1038/nrm3838>
- Hardy, A., Seguin, C., Brion, A., Laval, P., Schaaf, P., Fournel, S., Bourel-Bonnet, L., Frisch, B., & De Giorgi, M. (2018).  $\beta$ -Cyclodextrin-Functionalized Chitosan/Alginate Compact Polyelectrolyte Complexes (CoPECs) as Functional Biomaterials with Anti-Inflammatory Properties. *ACS Appl Mater Interfaces*, 10(35), 29347-29356. <https://doi.org/10.1021/acsami.8b09733>
- Hassan, U. A., Hussein, M. Z., Alitheen, N. B., Yahya Ariff, S. A., & Masarudin, M. J. (2018). In vitro cellular localization and efficient accumulation of fluorescently tagged biomaterials from monodispersed chitosan nanoparticles for elucidation of controlled release pathways for drug delivery systems. *Int J Nanomedicine*, 13, 5075-5095. <https://doi.org/10.2147/IJN.S164843>
- Hayes, J., Peruzzi, P. P., & Lawler, S. (2014). MicroRNAs in cancer: biomarkers, functions and therapy. *Trends Mol Med*, 20(8), 460-469. <https://doi.org/10.1016/j.molmed.2014.06.005>
- Howlander, N., Cronin, K. A., Kurian, A. W., & Andridge, R. (2018). Differences in Breast Cancer Survival by Molecular Subtypes in the United States. *Cancer Epidemiol Biomarkers Prev*, 27(6), 619-626. <https://doi.org/10.1158/1055-9965.Epi-17-0627>
- Hu, L., Ye, H., Huang, G., Luo, F., Liu, Y., Liu, Y., Yang, X., Shen, J., Liu, Q., & Zhang, J. (2016). Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. *Tumour Biol*, 37(2), 2691-2702. <https://doi.org/10.1007/s13277-015-4111-x>
- Huang, H. Y., Lin, Y. C., Cui, S., Huang, Y., Tang, Y., Xu, J., Bao, J., Li, Y., Wen, J., Zuo, H., Wang, W., Li, J., Ni, J., Ruan, Y., Li, L., Chen, Y., Xie, Y., Zhu, Z., Cai, X., . . . Huang, H. D. (2022). miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions. *Nucleic Acids Res*, 50(D1), D222-d230. <https://doi.org/10.1093/nar/gkab1079>
- Indrayanto, G., Putra, G. S., & Suhud, F. (2021). Validation of in-vitro bioassay methods: Application in herbal drug research. *Profiles Drug Subst Excip Relat Methodol*, 46, 273-307. <https://doi.org/10.1016/bs.podrm.2020.07.005>

- Jadidi-Niaragh, F., Atyabi, F., Rastegari, A., Mollarazi, E., Kiani, M., Razavi, A., Yousefi, M., Kheshtchin, N., Hassannia, H., Hadjati, J., & Shokri, F. (2016). Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles. *Tumour Biol*, 37(6), 8403-8412. <https://doi.org/10.1007/s13277-015-4732-0>
- Joo, J. (2021). Diagnostic and Therapeutic Nanomedicine. *Adv Exp Med Biol*, 1310, 401-447. [https://doi.org/10.1007/978-981-33-6064-8\\_15](https://doi.org/10.1007/978-981-33-6064-8_15)
- Jyothi, N. V., Prasanna, P. M., Sakarkar, S. N., Prabha, K. S., Ramaiah, P. S., & Srawan, G. Y. (2010). Microencapsulation techniques, factors influencing encapsulation efficiency. *J Microencapsul*, 27(3), 187-197. <https://doi.org/10.3109/02652040903131301>
- Kauanova, S., Urazbayev, A., & Vorobjev, I. (2021). The Frequent Sampling of Wound Scratch Assay Reveals the “Opportunity” Window for Quantitative Evaluation of Cell Motility-Impeding Drugs [Original Research]. *Frontiers in Cell and Developmental Biology*, 9. <https://doi.org/10.3389/fcell.2021.640972>
- Kaur, P., Nagaraja, G. M., Zheng, H., Gizachew, D., Galukande, M., Krishnan, S., & Asea, A. (2012). A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. *BMC Cancer*, 12, 120. <https://doi.org/10.1186/1471-2407-12-120>
- Kiran, A., Kumar, N., & Mehandia, V. (2021). Distinct Modes of Tissue Expansion in Free Versus Earlier-Confined Boundaries for More Physiological Modeling of Wound Healing, Cancer Metastasis, and Tissue Formation. *ACS Omega*, 6(17), 11209-11222. <https://doi.org/10.1021/acsomega.0c06232>
- Kong, Y. W., Ferland-McCollough, D., Jackson, T. J., & Bushell, M. (2012). microRNAs in cancer management. *Lancet Oncol*, 13(6), e249-258. [https://doi.org/10.1016/s1470-2045\(12\)70073-6](https://doi.org/10.1016/s1470-2045(12)70073-6)
- Leung, H.-W., Zhao, S.-M., Yue, G. G.-L., Lee, J. K.-M., Fung, K.-P., Leung, P.-C., Tan, N.-H., & Lau, C. B.-S. (2015). RA-XII inhibits tumour growth and metastasis in breast tumour-bearing mice via reducing cell adhesion and invasion and promoting matrix degradation. *Scientific Reports*, 5(1), 16985. <https://doi.org/10.1038/srep16985>
- Li, D., Hu, J., Hongming, S., Xu, H., Wu, C., Zhao, B., Xie, D., Wu, T., Zhao, J., & Fang, L. (2017). MiR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. *American journal of translational research*, 9, 2276-2285.
- Li, X., Hong, L., Zhao, Y., Jin, H., Fan, R., Du, R., Xia, L., Luo, G., & Fan, D. (2007). A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax. *Biochem Cell Biol*, 85(6), 741-750. <https://doi.org/10.1139/o07-141>
- Li, Y., Zhan, Z., Yin, X., Fu, S., & Deng, X. (2021). Targeted Therapeutic Strategies for Triple-Negative Breast Cancer. *Front Oncol*, 11, 731535. <https://doi.org/10.3389/fonc.2021.731535>

- Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., Cristofanilli, M., Hortobagyi, G. N., & Pusztai, L. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*, 26(8), 1275-1281. <https://doi.org/10.1200/jco.2007.14.4147>
- Malumbres, M., & Barbacid, M. (2009). Cell cycle, CDKs and cancer: a changing paradigm. *Nat Rev Cancer*, 9(3), 153-166. <https://doi.org/10.1038/nrc2602>
- Mathe, A., Scott, R. J., & Avery-Kiejda, K. A. (2015). MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. *Int J Mol Sci*, 16(12), 28347-28376. <https://doi.org/10.3390/ijms161226090>
- Mayr, C., & Bartel, D. P. (2009). Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. *Cell*, 138(4), 673-684. <https://doi.org/10.1016/j.cell.2009.06.016>
- Mersin, H., Yildirim, E., Berberoglu, U., & Gülben, K. (2008). The prognostic importance of triple negative breast carcinoma. *Breast*, 17(4), 341-346. <https://doi.org/10.1016/j.breast.2007.11.031>
- Miranda Furtado, C. L., Dos Santos Luciano, M. C., Silva Santos, R. D., Furtado, G. P., Moraes, M. O., & Pessoa, C. (2019). Epidrugs: targeting epigenetic marks in cancer treatment. *Epigenetics*, 14(12), 1164-1176. <https://doi.org/10.1080/15592294.2019.1640546>
- Motiei, M., Kashanian, S., Lucia, L. A., & Khazaei, M. (2017). Intrinsic parameters for the synthesis and tuned properties of amphiphilic chitosan drug delivery nanocarriers. *J Control Release*, 260, 213-225. <https://doi.org/10.1016/j.jconrel.2017.06.010>
- Moutinho, C., & Esteller, M. (2017). MicroRNAs and Epigenetics. *Adv Cancer Res*, 135, 189-220. <https://doi.org/10.1016/bs.acr.2017.06.003>
- Muhammad, N., Bhattacharya, S., Steele, R., & Ray, R. B. (2016). Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. *Oncotarget*, 7(36), 58595-58605. <https://doi.org/10.18632/oncotarget.11193>
- Mustacchi, G., & De Laurentiis, M. (2015). The role of taxanes in triple-negative breast cancer: literature review. *Drug Des Devel Ther*, 9, 4303-4318. <https://doi.org/10.2147/dddt.S86105>
- O'Toole, S. A., Beith, J. M., Millar, E. K., West, R., McLean, A., Cazet, A., Swarbrick, A., & Oakes, S. R. (2013). Therapeutic targets in triple negative breast cancer. *J Clin Pathol*, 66(6), 530-542. <https://doi.org/10.1136/jclinpath-2012-201361>
- Ozawa, P. M. M., Alkhilaiwi, F., Cavalli, I. J., Malheiros, D., de Souza Fonseca Ribeiro, E. M., & Cavalli, L. R. (2018). Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. *Breast Cancer Res Treat*, 172(3), 713-723. <https://doi.org/10.1007/s10549-018-4925-5>
- Panwar, P., Pandey, B., Lakhera, P. C., & Singh, K. P. (2010). Preparation, characterization, and in vitro release study of albendazole-encapsulated



- nanosize liposomes. *Int J Nanomedicine*, 5, 101-108. <https://doi.org/10.2147/ijn.s8030>
- Parise, C. A., & Caggiano, V. (2017). Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors. *Breast Cancer Res Treat*, 165(3), 743-750. <https://doi.org/10.1007/s10549-017-4383-5>
- Peng, Y., & Croce, C. M. (2016). The role of MicroRNAs in human cancer. *Signal Transduction and Targeted Therapy*, 1(1), 15004. <https://doi.org/10.1038/sigtrans.2015.4>
- Piva, R., Spandidos, D. A., & Gambari, R. (2013). From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). *Int J Oncol*, 43(4), 985-994. <https://doi.org/10.3892/ijo.2013.2059>
- Pochapski, D. J., Carvalho dos Santos, C., Leite, G. W., Pulcinelli, S. H., & Santilli, C. V. (2021). Zeta Potential and Colloidal Stability Predictions for Inorganic Nanoparticle Dispersions: Effects of Experimental Conditions and Electrokinetic Models on the Interpretation of Results. *Langmuir*, 37(45), 13379-13389. <https://doi.org/10.1021/acs.langmuir.1c02056>
- Pulaski, B. A., & Ostrand-Rosenberg, S. (2000). Mouse 4T1 Breast Tumor Model. *Current Protocols in Immunology*, 39(1), 20.22.21-20.22.16. <https://doi.org/https://doi.org/10.1002/0471142735.im2002s39>
- Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J. S., Akslen, L. A., Evans, A. J., Blamey, R., Reis-Filho, J. S., Foulkes, W. D., & Ellis, I. O. (2009). Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. *Clin Cancer Res*, 15(7), 2302-2310. <https://doi.org/10.1158/1078-0432.Ccr-08-2132>
- Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003). Cell migration: integrating signals from front to back. *Science*, 302(5651), 1704-1709.
- Ru, P., Steele, R., Hsueh, E. C., & Ray, R. B. (2011). Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. *Genes Cancer*, 2(7), 720-727. <https://doi.org/10.1177/1947601911425832>
- Rupaimoole, R., & Slack, F. J. (2017). MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. *Nat Rev Drug Discov*, 16(3), 203-222. <https://doi.org/10.1038/nrd.2016.246>
- Santos, J. C., Lima, N. D. S., Sarian, L. O., Matheu, A., Ribeiro, M. L., & Derchain, S. F. M. (2018). Exosome-mediated breast cancer chemoresistance via miR-155 transfer. *Sci Rep*, 8(1), 829. <https://doi.org/10.1038/s41598-018-19339-5>
- Satriyo, Pamungkas B., Haryana, S. M., Aryandono, T., Yeh, Chi-Tai. (2019). MicroRNA Profiling and Potential Treatment of 4-AAQB Against Oncomir in Triple Negative Breast Cancer (Doctoral dissertation). Retrieved from <http://etd.repository.ugm.ac.id/penelitian/detail/178726>.

- Schrörs, B., Boegel, S., Albrecht, C., Bukur, T., Bukur, V., Holtsträter, C., Ritzel, C., Manninen, K., Tadmor, A. D., Vormehr, M., Sahin, U., & Löwer, M. (2020). Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model [Original Research]. *Frontiers in Oncology*, 10. <https://doi.org/10.3389/fonc.2020.01195>
- Sharma, S., Khadimallah, I., Corya, A. W., Ali, Y. O., Rao, X., Liu, Y., & Lu, H.-C. (2018). Presymptomatic change in microRNAs modulates Tau pathology. *Scientific Reports*, 8(1), 9251. <https://doi.org/10.1038/s41598-018-27527-6>
- Silvestro, I., Francolini, I., Di Lisio, V., Martinelli, A., Pietrelli, L., Scotto d'Abusco, A., Scoppio, A., & Piozzi, A. (2020). Preparation and Characterization of TPP-Chitosan Crosslinked Scaffolds for Tissue Engineering. *Materials (Basel)*, 13(16). <https://doi.org/10.3390/ma13163577>
- Slade, D. (2019). Mitotic functions of poly(ADP-ribose) polymerases. *Biochem Pharmacol*, 167, 33-43. <https://doi.org/10.1016/j.bcp.2019.03.028>
- Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., Koh, H., Grischke, E. M., Frenzel, M., Lin, Y., Barriga, S., Smith, I. C., Bourayou, N., & Llombart-Cussac, A. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. *J Clin Oncol*, 35(25), 2875-2884. <https://doi.org/10.1200/jco.2017.73.7585>
- Spinner, D. M. (2001). MTT growth assays in ovarian cancer. *Methods Mol Med*, 39, 175-177. <https://doi.org/10.1385/1-59259-071-3:175>
- Sun, H., Zhou, Y., Jiang, H., & Xu, Y. (2020). Elucidation of Functional Roles of Sialic Acids in Cancer Migration. *Front Oncol*, 10, 401. <https://doi.org/10.3389/fonc.2020.00401>
- Sun, S. B., Liu, P., Shao, F. M., & Miao, Q. L. (2015). Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer. *Int J Clin Exp Med*, 8(10), 19670-19681.
- Tan, X., Peng, J., Fu, Y., An, S., Rezaei, K., Tabbara, S., Teal, C. B., Man, Y. G., Brem, R. F., & Fu, S. W. (2014). miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. *Breast Cancer Res*, 16(5), 435. <https://doi.org/10.1186/s13058-014-0435-5>
- Telli, M. L., & Ford, J. M. (2010). Novel treatment approaches for triple-negative breast cancer. *Clin Breast Cancer*, 10 Suppl 1, E16-22. <https://doi.org/10.3816/CBC.2010.s.003>
- Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H. C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., Xu, B., Campone, M., Lerzo, G. L., Peck, R. A., Mukhopadhyay, P., Vahdat, L. T., & Roché, H. H. (2007). Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. *J Clin Oncol*, 25(33), 5210-5217. <https://doi.org/10.1200/jco.2007.12.6557>

- Thomssen, C., Pierga, J. Y., Pritchard, K. I., Biganzoli, L., Cortes-Funes, H., Petr kov , K., Kaufman, B., Duenne, A., & Smith, I. (2012). First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. *Oncology*, 82(4), 218-227. <https://doi.org/10.1159/000336892>
- Todaka, H., Higuchi, T., & Sakamoto, S. (2016). Pathophysiological events induced by alteration of microRNA biogenesis pathway. *Hikaku seiri seikagaku(Comparative Physiology and Biochemistry)*, 33(4), 183-190. <https://doi.org/10.3330/hikakuseiriseika.33.183>
- Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011). Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. *Mol Ther*, 19(6), 1116-1122. <https://doi.org/10.1038/mt.2011.48>
- Troester, M. A., Herschkowitz, J. I., Oh, D. S., He, X., Hoadley, K. A., Barbier, C. S., & Perou, C. M. (2006). Gene expression patterns associated with p53 status in breast cancer. *BMC Cancer*, 6, 276. <https://doi.org/10.1186/1471-2407-6-276>
- Tsai, H. F., & Hsu, P. N. (2017). Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets. *J Biomed Sci*, 24(1), 35. <https://doi.org/10.1186/s12929-017-0341-0>
- Veldwijk, M. R., Neumaier, C., Gerhardt, A., Giordano, F. A., S tterlin, M., Herskind, C., & Wenz, F. (2015). Comparison of the proliferative and clonogenic growth capacity of wound fluid from breast cancer patients treated with and without intraoperative radiotherapy. *Translational Cancer Research*, 4(2), 173-177. <https://tcr.amegroups.com/article/view/4233>
- Ventola, C. L. (2012). The nanomedicine revolution: part 1: emerging concepts. *P t*, 37(9), 512-525.
- Veronese, F. M., & Mero, A. (2008). The impact of PEGylation on biological therapies. *BioDrugs*, 22(5), 315-329. <https://doi.org/10.2165/00063030-200822050-00004>
- Wang, C., Zheng, X., Shen, C., & Shi, Y. (2012). MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. *J Exp Clin Cancer Res*, 31(1), 58. <https://doi.org/10.1186/1756-9966-31-58>
- Wang, X., Decker, C. C., Zechner, L., Krstin, S., & Wink, M. (2019). In vitro wound healing of tumor cells: inhibition of cell migration by selected cytotoxic alkaloids. *BMC Pharmacology and Toxicology*, 20(1), 4. <https://doi.org/10.1186/s40360-018-0284-4>
- Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., & Bader, A. G. (2010). Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. *Cancer Res*, 70(14), 5923-5930. <https://doi.org/10.1158/0008-5472.Can-10-0655>
- Xie, M., Li, M., Vilborg, A., Lee, N., Shu, M. D., Yartseva, V., Sestan, N., & Steitz, J. A. (2013). Mammalian 5'-capped microRNA precursors that



- generate a single microRNA. *Cell*, 155(7), 1568-1580. <https://doi.org/10.1016/j.cell.2013.11.027>
- Xu, J.-Z., Shao, C.-C., Wang, X.-J., Zhao, X., Chen, J.-Q., Ouyang, Y.-X., Feng, J., Zhang, F., Huang, W.-H., Ying, Q., Chen, C.-F., Wei, X.-L., Dong, H.-Y., Zhang, G.-J., & Chen, M. (2019). circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis. *Cell Death & Disease*, 10(3), 175. <https://doi.org/10.1038/s41419-019-1382-y>
- Yan, X., Chen, X., Liang, H., Deng, T., Chen, W., Zhang, S., Liu, M., Gao, X., Liu, Y., Zhao, C., Wang, X., Wang, N., Li, J., Liu, R., Zen, K., Zhang, C. Y., Liu, B., & Ba, Y. (2014). miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. *Mol Cancer*, 13, 220. <https://doi.org/10.1186/1476-4598-13-220>
- Yardley, D. A., Shipley, D. L., Peacock, N. W., Shastry, M., Midha, R., Priego, V. M., & Hainsworth, J. D. (2015). Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer. *Breast Cancer Research and Treatment*, 152(3), 557-567. <https://doi.org/10.1007/s10549-015-3482-4>
- Zhang, F., Liu, M. R., & Wan, H. T. (2014). Discussion about several potential drawbacks of PEGylated therapeutic proteins. *Biol Pharm Bull*, 37(3), 335-339. <https://doi.org/10.1248/bpb.b13-00661>
- Zhang, W., Xu, W., Lan, Y., He, X., Liu, K., & Liang, Y. (2019). Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer. *Int J Nanomedicine*, 14, 5287-5301. <https://doi.org/10.2147/ijn.S203113>
- Zhang, Z., Li, J., Huang, Y., Peng, W., Qian, W., Gu, J., Wang, Q., Hu, T., Ji, D., Ji, B., Zhang, Y., Wang, S., & Sun, Y. (2018). Upregulated miR-1258 regulates cell cycle and inhibits cell proliferation by directly targeting E2F8 in CRC. *Cell Prolif*, 51(6), e12505. <https://doi.org/10.1111/cpr.12505>
- Zhao, Y., & Adjei, A. A. (2015). Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. *Oncologist*, 20(6), 660-673. <https://doi.org/10.1634/theoncologist.2014-0465>
- Zheng, T., Zhang, X., Wang, Y., & Yu, X. (2016). Predicting associations between microRNAs and target genes in breast cancer by bioinformatics analyses. *Oncol Lett*, 12(2), 1067-1073. <https://doi.org/10.3892/ol.2016.4731>
- Zhou, X., Yang, G., & Guan, F. (2020). Biological Functions and Analytical Strategies of Sialic Acids in Tumor. *Cells*, 9(2). <https://doi.org/10.3390/cells9020273>